Clinical Trial Update: Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating the combination of plerixafor and bortezomib in relapsed or relapsed/refractory multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Plerixafor (Plerixafor)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-09-29